NCT05561387: Phase 3: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma NDMM
- Recruiting
- Dec 1, 2022
- 1 min read
Updated: Jan 27, 2024
SWOG - S2209 - Southwest Oncology Group
NCT05561387: Phase 3: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
NCT05561387: Phase 3: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are considered frail or intermediate-fit based on age, comorbidities, and functional status.
Sponsor
Collaborator
ClinicalTrials.gov Identifier: NCT05561387
Official Title: A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
First Posted : September 30, 2022
Click here for details on ClinicalTrials.gov
Drug: Bortezomib
Drug: Daratumumab and Hyaluronidase-fihj
Drug: Dexamethasone
Drug: Lenalidomide
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Patient Information - FDA Approved Drugs Multiple Myeloma
Location
United States
